Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.41 |
| ▸ | CNR1 | P21554 | 6/20 | 0.41 |
| ▸ | ACHE | P22303 | 5/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | F2RL3 | Q96RI0 | 5/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | F2R | P25116 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14442048 | 0.84 | ELANE (0.47) | CNR2CNR1ACHEL3MBTL1F2RL3 | |
| SCHEMBL4006988 | 0.83 | NPC1 (0.34) | CNR2CNR1ACHE | |
| Pyridine SCHEMBL5206041 | 0.82 | CNR2 (0.35) | CNR2CNR1ACHEL3MBTL1F2RL3 | |
| SCHEMBL3513839 | 0.82 | CNR2 (0.42) | CNR2CNR1ACHEL3MBTL1F2RL3 | |
| SCHEMBL5518753 | 0.81 | L3MBTL1 (0.58) | CNR2CNR1ACHEL3MBTL1F2RL3 | |
| SCHEMBL3514358 | 0.80 | CNR2 (0.39) | CNR2CNR1ACHEL3MBTL1F2RL3 | |
| SCHEMBL2470918 | 0.79 | CNR2 (0.45) | CNR2CNR1ACHEL3MBTL1F2RL3 | |
| SCHEMBL30183407 | 0.79 | CNR2 (0.45) | CNR2CNR1ACHEL3MBTL1F2RL3 | |
| SCHEMBL29644071 | 0.79 | CNR2 (0.45) | CNR2CNR1ACHEL3MBTL1F2RL3 | |
| SCHEMBL3517141 | 0.79 | CNR2 (0.45) | CNR2CNR1ACHEL3MBTL1F2RL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-03-17 | — | — | US | disclosed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | CNR2 2155/4885CNR1 2219/4885ACHE 2085/4885 |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | CNR2 2663/4885CNR1 2997/4885ACHE 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.